ArticleEuropean journal of nuclear medicine and molecular imaging2024
Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2.
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide.Journal of structural biology: X · 2026Article
- Evaluation of molecular interactions of vaping juice components with ACE2 receptor.Scientific reports · 2026Article
- Natural Selection-Guided ACE2-Targeted Molecular Imaging: A New Paradigm for PET Tracer Development.Chemical & biomedical imaging · 2026Article
- PoMA-10: a dual-action antiviral disrupting SARS-CoV-2 Spike-ACE2 interaction and protecting lung tissue.Frontiers in pharmacology · 2026Article
- Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme.European journal of nuclear medicine and molecular imaging · 2025Article
- The future of pharmaceuticals: Artificial intelligence in drug discovery and development.Journal of pharmaceutical analysis · 2025Review
- Synthesis and Inhibitory Assessment of ACE2 Inhibitors for SARS-CoV-2: AnThe Journal of organic chemistry · 2025Article
- Synthesis, molecular docking, andRSC advances · 2025Article
- An ACE2 PET imaging agent derived fromEJNMMI radiopharmacy and chemistry · 2024Article
- Development of radiofluorinated MLN-4760 derivatives for PET imaging of the SARS-CoV-2 entry receptor ACE2.European journal of nuclear medicine and molecular imaging · 2024Article
- Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe angiotensin converting enzyme 2 (ACE2) plays a regulatory role in the cardiovascular system and serves SARS-CoV-2 as an entry receptor. The aim of this study was to synthesize and evaluate radiofluorinated derivatives of the ACE2 inhibitor MLN-4760. [
methodsComputational molecular modeling, based on the structures of human ACE2 (hACE2) and mouse ACE2 (mACE2), revealed that the ACE2-binding modes of F-MLN-4760 and F-Aza-MLN-4760 were similar to that of MLN-4760. Co-crystallization of the hACE2/F-MLN-4760 protein complex was performed for confirmation. Displacement experiments using [
resultsCrystallography data revealed an equal hACE2-binding mode for F-MLN-4760 as previously found for MLN-4760. Moreover, computer-based modeling indicated that similar binding to hACE2 and mACE2 holds true for both, F-MLN-4760 and F-Aza-MLN-4760, as is the case for MLN-4760. The IC
conclusionBoth radiotracers showed specific and selective binding to ACE2 in vitro and in vivo. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.